Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Raymond P. Abratt; D. Brune; Meletios A Dimopoulos; J. Kliment; J. Breza; Fp Selvaggi; Philippe Beuzeboc; Tomasz Demkow; Stéphane Oudard

doi:10.1093/annonc/mdh429

Article2003

864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study

Raymond P. Abratt, D. Brune, Meletios A Dimopoulos, J. Kliment, J. Breza, P. Selvaggi, Philippe Beuzeboc, Tomasz Demkow, Stéphane Oudard

Article2025

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida, María‐Victoria Mateos, Tondre T. Buck, Richard LeBlanc, Jiří Minařík, Hartmut Goldschmidt, Rick Zhang, Dorothée Sémiond, Florence Suzan, Maya Stefanova-Urena, Vera Hermina Kalika Koch, Philippe Moreau

Article2005

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

G.F. Samelis, Haralabos P. Kalofonos, Αδάμος Αδάμου, Paris Kosmides, Dimosthenis Skarlos, Gerasimos Aravantinos, Christos Kiamouris, Oneynadum Adimchi, George Fountzilas, Meletios A Dimopoulos

Corrigendum2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida,

Article2004

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

Meletios A Dimopoulos, Christos Kiamouris, Dimitra Gika, Charalambos Deliveliotis, A. Giannopoulos, Anastasios Zervas, Christos Alamanis, C. Constantinidis, Michael Koutsilieris

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Discussion(0)

Related publications

864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study